Stone Pharmaceuticals' research and development investment increased by 64% in the first three quarters of the new drug sales revenue of 9.5 billion yuan

yesterday, Stone Pharmaceuticals released its first three quarters 2019 results. The report showed that Stone Pharmaceuticals recorded revenue of RMB16,761 million in the first three quarters, an increase of 27.5% YoY, and investment in research and development of RMB1.502 billion, up 64% YoY from RMB916 million in the same period last year. About 11.2% of the revenue from the pharmaceutical business.

the first three quarters of 2019, Shi Pharmaceutical Group's pharmaceutical business maintained strong growth, with sales revenue of RMB13,387 million, up 35.1% YoY, according to the company's financial results. Among them, innovative pharmaceutical products (including Umbipu (butyl phenol softgels and injections), polymethytin (hydrochloric acid polyjubi star lipid body injections), Zin youli (polyglycol recombinant human granulocyte stimulant injections), Kerai (injected with yew alcohol (white protein binding), Elyone (lysin injection), Nolinin Sales revenue of (imathionate tablets), Oranin (Orasitan capsules and freeze-dried powder needles) and Xuanning (Malay acid L-chloride tablets) was RMB9.525 billion, an increase of 51.9% YoY;
Among them, Entip maintained rapid growth, sales revenue increased by 35.7%. The growth of Domesin and Zinli continued to pick up, with sales revenue increasing by 118.1% and 129.5% respectively during the period. Since its launch in March last year, sales have grown rapidly, with sales growth of 590.4% over the period, and Stone Pharmaceuticals said it is committed to making Kerai another heavyweight product. In addition, sales growth of the anti-tumor portfolio during the period reached 170.7%, becoming the emerging growth engine of Stone Pharmaceutical Group.In the September 24 volume procurement tender, the stone drug clopidogrel tablets successfully won the bid, achieving about 39% of the expected procurement volume, to ensure that the product in the next few years sales revenue. At present, Stone Pharmaceutical Group has passed a consistent evaluation of 16 products, Shi Pharmaceutical said, with the advantages of production costs and home-made raw materials, the promotion of centralized procurement will bring Stone Pharmaceuticals to quickly occupy the market opportunities.On the other hand, sales of stone medicine vitamin C products increased by 15.3% to 1.596 billion yuan. Revenue from antibiotic products was $715 million, down 17.2% year-on-year. Other businesses, including caffeine additives and vitamin C supplements, grew steadily.
(Medical Rubik's Cube)